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Abstract
Objectives: To systematically assess the evidence of Craniosacral Therapy (CST) for the treatment of chronic pain.
Methods: PubMed, Central, Scopus, PsycInfo and Cinahl were searched up to August 2018. Randomized controlled
trials (RCTs) assessing the effects of CST in chronic pain patients were eligible. Standardized mean differences (SMD)
and 95% confidence intervals (CI) were calculated for pain intensity and functional disability (primary outcomes)
using Hedges’ correction for small samples. Secondary outcomes included physical/mental quality of life, global
improvement, and safety. Risk of bias was assessed using the Cochrane tool.
Results: Ten RCTs of 681 patients with neck and back pain, migraine, headache, fibromyalgia, epicondylitis, and
pelvic girdle pain were included. CST showed greater post intervention effects on: pain intensity (SMD = -0.32,
95%CI = [− 0.61,-0.02]) and disability (SMD = -0.58, 95%CI = [− 0.92,-0.24]) compared to treatment as usual; on pain
intensity (SMD = -0.63, 95%CI = [− 0.90,-0.37]) and disability (SMD = -0.54, 95%CI = [− 0.81,-0.28]) compared to
manual/non-manual sham; and on pain intensity (SMD = -0.53, 95%CI = [− 0.89,-0.16]) and disability (SMD = -0.58,
95%CI = [− 0.95,-0.21]) compared to active manual treatments. At six months, CST showed greater effects on pain
intensity (SMD = -0.59, 95%CI = [− 0.99,-0.19]) and disability (SMD = -0.53, 95%CI = [− 0.87,-0.19]) versus sham.
Secondary outcomes were all significantly more improved in CST patients than in other groups, except for six-
month mental quality of life versus sham. Sensitivity analyses revealed robust effects of CST against most risk of bias
domains. Five of the 10 RCTs reported safety data. No serious adverse events occurred. Minor adverse events were
equally distributed between the groups.
Discussion: In patients with chronic pain, this meta-analysis suggests significant and robust effects of CST on pain
and function lasting up to six months. More RCTs strictly following CONSORT are needed to further corroborate the
effects and safety of CST on chronic pain.
Protocol registration at Prospero: CRD42018111975.
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Background
Chronic pain disorders are the leading global cause of dis-
ability and are still increasing in prevalence [1]. Low back
and neck pain, headache and migraine considerably affect
all age groups from the beginning of adolescence to
middle-aged and older adults [1]. The often limited effects
and potential side effects of pharmacological treatments
for chronic musculoskeletal pain conditions [2] may be
reasons why patients frequently use complementary ther-
apies [3–5]. Among them, Craniosacral Therapy (CST) is
a typically requested treatment for complaints of the back
and neck, headache and migraine, and associated stress-
related and mental health problems [6, 7].
Derived from osteopathic manipulative treatment, CST
consists of mindful, non-invasive fascial palpation tech-
niques applied between the cranium and sacrum [8, 9].
Besides releasing myofascial structures, CST intends to
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normalize sympathetic nerve activity, often increased in
chronic pain patients, by modifying craniosacral body
rhythms [10, 11]. Reducing physiological arousal and
switching to the parasympathetic mode [12] has been
shown to enhance the body’s ability for physiological regu-
lation and tissue relaxation [13–17], and to decrease
chronic pain [18, 19]. While the specific mechanisms of
CST are still understudied, clinical trials have shown pre-
liminary evidence for CST on improving patient-reported
outcomes, albeit with often unclear risk of bias due to lim-
ited methodological study quality [20–22]. To date, RCTs
have only been summarized qualitatively [20–24], and no
meta-analysis has provided quantitative information about
the mean effects of CST.
By conducting a systematic review and meta-analysis,
we aimed to pool the existing evidence of CST in pain
patients and to assess whether this evidence is robust
against the possible risk of systematic bias.
Materials and methods
This review was conducted in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [25] and the rec-
ommendations of the Cochrane Collaboration [26]. A
protocol of the methods used was previously registered
at Prospero (CRD42018111975).
Eligibility criteria
Studies were eligible if they were published as: either full-
texts or abstracts of randomized controlled trials (RCTs)
or randomized crossover trials that included adult patients
with a chronic, non-malignant pain condition of any
cause, duration, or intensity. Studies had to examine a
type of CST regardless of length or content. Eligible con-
trol interventions were active or inactive comparators
such as: treatment as usual, waiting list, sham, pharmaco-
logical therapies, or non-pharmacological comparators.
To be included, studies had to report at least one primary
or secondary outcome assessed at the end of the interven-
tion period or at a follow-up point closest to six months
after randomization. Pain intensity and functional disabil-
ity were defined as primary outcomes. Secondary out-
comes included physical quality of life, mental quality of
life, global improvement, and safety [27]. If a study re-
ported on more than one instrument assessing the same
outcome, disease-specific instruments were preferred over
generic ones, multi-item over single-item ones, and
clinician-rated over patient-rated ones. Safety was opera-
tionalized as the number of adverse events (AE) or study
withdrawals due to AEs. AEs were defined as any unto-
ward medical occurrence in a patient, which did not have
to have a defined causal relationship with the study treat-
ment. Cases of any untoward medical occurrence that, at
any dose, has resulted in death, was life-threatening,
required inpatient hospitalization, or caused persistent or
significant disability were rated as serious AEs [28].
Studies were excluded if they were non-randomized
trials, included samples of children or adolescents, or
tested interventions that were not defined as CST by the
trial authors (for example specific techniques related to
cranial osteopathy).
Literature search
We searched PubMed, PsycInfo, Central Trials, Cinahl,
and Scopus from inception to August 2018 by browsing ti-
tles, abstracts, and keywords using the search terms “cra-
niosacral” or “cranio sacral”. No language restrictions
were applied. We manually searched reference lists of pre-
vious studies and reviews, PhD and DO theses, and web-
sites of international craniosacral associations to retrieve
additional articles. For ongoing and unpublished studies,
we searched international trial registries of the NIC and
WHO and conference proceedings. Two reviewers (HH
and HC) independently screened titles and abstracts of
those studies and assessed the remaining full-texts for eli-
gibility. Any disagreements were rechecked with a third
reviewer (RL) until consensus was achieved.
Data extraction
Two reviewers (RL and HC) independently extracted
data from the eligible studies including: their origin, the
studied pain condition, the sample size, the mean age of
the patients, the percentage of included women, the
type, content and lengths of the experimental and con-
trol intervention, the outcomes and assessment points
included in the meta-analysis, reported AEs, and sources
of funding. Discrepancies were rechecked with a third
reviewer (HH) until consensus was achieved.
Risk of bias in individual studies
Again, two reviewers (RL and TS) independently
assessed the risk of: selection, performance, detection,
attrition, reporting, and other bias using the Cochrane
risk of bias tool [26]. Each domain was judged as either,
‘low risk of bias’ if all requirements were adequately ful-
filled, ‘high risk of bias’ if the requirements were not ad-
equately fulfilled, and as ‘unclear risk of bias’ if
insufficient data for a judgment was provided. Divergent
judgments were rechecked with a third reviewer (HC)
until consensus was achieved.
Statistical analyses
Assessment of overall effect sizes
Pairwise meta-analyses were conducted by Review Manager
Software (RevMan, Version 5.3, The Nordic Cochrane
Centre, Copenhagen) using random-effects models (inverse
variance method). Effects were pooled for studies comparing
CST to treatment as usual or wait list, manual or non-
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manual sham treatments, active pharmacological treatments,
and similar active non-pharmacological treatments at the re-
spective time point. Standardized mean differences (SMDs)
with 95% confidence intervals (CIs) were calculated, which
indicate the difference in means between groups divided by
the pooled standard deviation (SD) using Hedges’ correction
for small samples (N) [26]. Where no SDs were available,
they were calculated from standard errors, CIs or t-values
[26], or were requested from trial authors by email. For pain
intensity and functional disability, a negative SMD indicated
greater effects of CST compared to the respective control
condition. For the quality of life measures and the global im-
provement ratings, a positive SMD indicated greater effects
of CST compared to control. In accordance with
Cohen’s categories, Hedges’ g can be interpreted as: a
small effect, in cases of an SMD of 0.2–0.5; as a
medium effect in cases of an SMD of 0.5–0.8; and as
a large effect in cases of an SMD of > 0.8 [29]. Re-
spective categories were applied for negative SMDs.
Subgroup analyses
Subgroup analyses were considered for patients with dif-
ferent pain diagnoses and different types of CST but
could not be performed, as there were insufficient stud-
ies for those comparisons.
Assessment of heterogeneity
Chi2 statistics were used to explore statistical heterogen-
eity between studies, with a p-value of ≤ .10 indicating
significant heterogeneity. The magnitude of heterogen-
eity was categorized by the I2 with: I2 > 25%, I2 > 50%,
and I2 > 75% representing moderate, substantial, and
considerable heterogeneity, respectively [26, 30].
Sensitivity analyses
Where studies with high or unclear risk of bias were
pooled with those of low risk of bias, sensitivity analyses
were performed to test the robustness of significant ef-
fects. If substantial or considerable statistical heterogen-
eity was present in a meta-analysis, sensitivity analyses
were used to explain them as a possible consequence of
clinical heterogeneity in study quality, samples, or inter-
vention characteristics.
Risk of bias across studies
We intended to use visual analysis of funnel plots to as-
sess publication bias if more than 10 studies could be in-
cluded in a single meta-analysis [31].
Results
Literature search
The electronic database search revealed 540 articles
(Fig. 1). Two additional articles were retrieved from the
manual search. After removing duplicates and excluding
articles by screening titles and abstracts, 12 full-text arti-
cles were assessed for eligibility. Two further articles [32,
33] had to be excluded as they did not report sufficient
data for meta-analysis. Another article was only pub-
lished as a study protocol [34] and a conference pro-
ceeding [35] but detailed data was provided by email.
Thus, a final sample of 10 RCTs published between
1999 and 2016 that included 681 patients were eligible
for meta-analysis [35–44].
Study characteristics
The characteristics of the included RCTs are presented in
Table 1. The RCTs were conducted in: the US [35, 42, 44],
Spain [38, 39, 43], Germany [41], Iceland [36], Poland
[37], and Sweden [40]. The trials included patients suffer-
ing from: tension-type headache [41], migraine [35, 36],
low back pain [37, 39], neck pain [41], fibromyalgia [38,
43], pelvic girdle pain [40], and lateral epicondylitis [44].
Sample sizes ranged from 20 to 123 with a median N of
62 and a median of 90% of women. The median age of the
total sample was 43.4 years with a range from 30.6 to 52.5
years. Studies provided 1 to 50 CST treatments with a me-
dian number of 7 treatments within a maximum of 25
weeks. While two studies used a single CST technique
[42, 44], the others implemented a more comprehensive,
semi-standardized treatment protocol [35–41, 43]. Con-
trol conditions included: treatment as usual [40], no treat-
ment [42], wait list [36], non-manual sham procedures
(disconnected devices) [35, 38, 43], manual sham [41, 44],
and active manual treatments such as trigger point ther-
apy [37] and soft tissue massage [39]. No study compared
CST to an active drug treatment.
Pain intensity was mostly measured using Numeric
Rating Scales (NRS) and Visual Analogue Scales (VAS)
[39–42, 44]. One study reported VAS scores as medians
only [40]. However, upon request, trial authors provided
means and SDs of the morning and evening pain ratings,
which were combined to an average pain score. Two
additional studies also assessed VAS/NRS data but did
not report related SDs [43] or provided incomplete out-
come data comprising of only 72% of the sample [35].
Thus, we had to include alternative measurements tak-
ing complete data from the Bodily Pain subscale of the
36-Item Short Form Health Survey (SF-36) and from a
pain diary assessing hours of severe headache per day.
One study, moreover, used the Intensity of Pain subscale
of the Laitinen Pain Indicator Questionnaire (LPIQ)
[37]. Functional disability was measured using the Head-
ache Impact Test (HIT-6) [36], the Limitation of Activity
subscale of the LPIQ [37], the Roland Morris Disability
Questionnaire (RMQ) [39], the Oswestry Disability
Index (ODI) [40], the Neck Disability Index (NDI) [41],
the Migraine Disability Assessment Score (MIDAS) [35],
the Physical Function subscale of the SF-36 [43], and the
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Patient Specific Functional Scale (PSFS) [44]. Physical
and mental quality of life were measured by sub- and
component-scores of the SF-12 and SF-36 [41, 43], In
addition, one study measured physical quality of life
using the European Quality of Life Measure (EQ. 5D)
and reported median changes [40]. Upon request, the
trial authors provided means and SDs, which led us to
calculate an additional meta-analysis although it in-
cluded only this RCT. Global improvement was assessed
by the Patient Global Impression of Improvement Scale
(PGII) [41] and the Clinical Global Impression of Im-
provement Scale (CGII) [38].
Risk of bias of individual studies
The risk of bias assessments are summarized in Figs. 2
and 3. Risk of selection bias was assessed as low in 60%
of the included studies [35, 37, 39–41, 44]. Two further
trials reported adequate random sequence generation
but did not provide information about allocation con-
cealment [38, 43]. Two trials [41, 44] ensured blinding
of participants. However, the overall risk of performance
bias was unclear or high for all but one of the trials, as
the therapists could not be blinded to treatment alloca-
tion or this information was missing. We assessed one of
the RCTs [41] as having low risk of performance bias, al-
though the therapists were not described as being
blinded, as secondary analyses had shown that the qual-
ity of the alliance to the assigned therapists did not sys-
tematically affect study outcomes [45]. Adequate
blinding of outcome assessors was reported by 40% of
the studies [38, 39, 41, 44], whereas 60% did not provide
sufficient information to assess the risk of detection bias.
The risk of attrition bias was evaluated as low in 90% of
the studies [35, 36, 38–44], the risk of selective reporting
as low in 40% [39–41, 43]. The risk of other bias was
assessed as unclear in 90% of the RCTs because of miss-
ing alpha-level adjustment [35, 38–40] or information
about sources of funding [36, 37, 42–44]. The other
studies reported having received no funding [38, 39],
university funding [41], or government research grants
[35, 40]. One of the trials also reported partial funding
from CST associations for the publication fee [41].
Risk of publication bias
Although funnel plots could not be created, the risk of
publication bias is likely to be low. Searches of trial
registries and conference proceedings revealed only one
unpublished study [35], which could be included, as the
trial authors provided all relevant data upon request.
Manual searches of non-peer reviewed literature re-
vealed two further RCTs [32, 33]. One of these [32] only
reported rates of response for those whose quality of life
Fig. 1 Flowchart of the literature search
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improved but did not define improvement, the other
RCT [33] did not report the sample sizes for each study
group. By dividing the total N by 2, the calculated
between-group effect sizes appeared unexpectedly high
in favor of CST. Thus, the exclusion of those two trials
will most probably not raise the risk of publication bias.
Assessment of overall effect sizes
Effects on primary outcomes
The pooled effects on pain intensity are shown in Fig. 4.
In comparison to treatment as usual, CST showed a sig-
nificant greater effect of a small size directly after the
intervention (2 RCTs, SMD= − 0.32, 95%CI = [− 0.61, −
0.02], I2 = 0%, N = 183) [40, 42]. In comparison to manual
and non-manual sham treatments, CST showed a signifi-
cant medium pooled effect directly post intervention (4
RCTs, SMD= − 0.63, 95%CI = [− 0.90, − 0.37], I2 = 0%,
N = 230) [35, 41, 43, 44]. By analyzing manual [41, 44] and
non-manual sham controls [35, 43] separately, CST was
found to be superior to manual sham with a greater
pooled effect size (2 RCTs, SMD= − 0.97, 95%CI = [− 1.44,
− 0.49], I2 = 0%, N = 77) compared to non-manual sham (2
R CTs, SMD= − 0.48, 95%CI = [− 0.80, − 0.16], I2 = 0%,
N = 153). At 6-months follow-up, the pooling of the ef-
fects resulted in a significant medium effect size in favor
of CST (2 RCTs, SMD= − 0.59, 95%CI = [− 0.99, − 0.19],
I2 = 25%, N = 138) [41, 43] in comparison to manual and
non-manual sham. In comparison to an active manual
control treatment directly after the intervention, CST was
found to produce greater effects resulting in a significant
medium pooled effect size (2 RCTs, SMD= − 0.53,
95%CI = [− 0.89, − 0.16], I2 = 0%, N = 119) [37, 39].
The pooled effects on functional disability are shown
in Fig. 5. In comparison to treatment as usual post inter-
vention, the pooling of effects resulted in a significant
greater medium effect size in favor of CST (2 RCTs,
SMD = − 0.58, 95%CI = [− 0.92, − 0.24], I2 = 0%, N = 143)
Fig. 2 Risk of bias of individual studies
Fig. 3 Risk of bias summary
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[36, 40]. In comparison to manual and non-manual
sham, the meta-analysis showed a medium post-
intervention effect (4 RCTs, SMD = − 0.54, 95%CI = [−
0.81, − 0.28], I2 = 0%, N = 230) [35, 41, 43, 44], while the
separate pooling of RCTs testing CST against manual
sham controls were found to have a greater effect (2
RCTs, SMD = − 0.76, 95%CI = [− 1.22, − 0.29], I2 = 0%,
N = 77) [41, 44] than RCTs testing CST against non-
manual sham controls (2 RCTs, SMD = − 0.44, 95%CI =
[− 0.78, − 0.10], I2 = 10%, N = 153) [35, 43]. The meta-
analysis at 6-months resulted in a significant medium ef-
fect size in favor of CST (2 RCTs, SMD = − 0.53,
95%CI = [− 0.87, − 0.19], I2 = 0%, N = 138) [41, 43] in
comparison to manual and non-manual sham. For the
comparison to an active manual control treatment post
intervention, the pooling of the study data revealed a sig-
nificant greater effect of a medium size in favor of CST
(2 RCTs, SMD = − 0.58, 95%CI = [− 0.95, − 0.21], I2 = 0%,
N = 119) [37, 39].
Effects on secondary outcomes
The pooled effects on physical quality of life are shown
in Fig. 6. In comparison to treatment as usual, the per-
formed analysis revealed a significant greater medium
post-intervention effect in favor of CST (1 RCT, SMD =
0.51, 95%CI = [0.15, 0.87], N = 123) [40]. In comparison
to manual and non-manual sham conditions, the meta-
analyses revealed a significant medium post-intervention
effect (2 RCTs, SMD = 0.59, 95%CI = [0.25, 0.93], I2 =
0%, N = 138) [41, 43] as well as a significant medium 6-
months follow-up effect (2 RCTs, SMD = 0.62, 95%CI =
[0.02, 1.21], I2 = 64%, N = 138) [41, 43] in favor of CST.
However, the meta-analysis of the follow-up effects re-
vealed significant heterogeneity.
The pooled effects on mental quality of life are
shown in Fig. 7. In comparison to manual and non-
manual sham controls, the meta-analyses revealed
small pooled effects in favor of CST, which were
found to be significant directly after the intervention
Fig. 4 Forest plot of pain intensity
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(2 RCTs, SMD = 0.35, 95%CI = [0.01, 0.69], I2 = 0%,
N = 138) [41, 43] but no longer at the 6-month
follow-up (2 RCTs, SMD = 0.29, 95%CI = [− 0.05,
0.63], I2 = 0%, N = 138) [41, 43].
The pooled effects on global improvement are shown in
Fig. 8. In comparison to manual and non-manual sham con-
trols, the meta-analyses resulted in a significant large pooled
effect in favor of CST post intervention (2 RCTs, SMD=
1.29, 95%CI = [0.93, 1.65], I2 = 0%, N= 146) [38, 41] and a
significant medium pooled effect six months after
randomization (2 RCTs, SMD=0.51, 95%CI = [0.18, 0.84],
I2 = 0%, N= 146) [38, 41].
Sensitivity analyses
By excluding studies with an unclear or high risk of
the respective bias from the comparisons to treatment
as usual, CST effects on pain intensity post
intervention were found to be robust only against the
risk of attrition bias, while the effects on functional
disability and physical quality of life were found to be
robust against the risk of selection, attrition, and
reporting bias.
In comparison to manual and non-manual sham
treatments, CST effects on pain intensity and func-
tional disability post intervention as well as six
months after randomization were still found to be
significant even if the respective studies with unclear
or high risk of selection, performance, detection, attri-
tion, reporting, and other source of bias were ex-
cluded. The effects of CST on physical and mental
quality of life in comparison to sham post interven-
tion were found to be robust only against the risk of
attrition and reporting bias. The significant follow-up
effect on physical quality of life were robust against
all risk of bias dimensions. This is also true for the
Fig. 5 Forest plot of functional disability
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post intervention and follow-up analyses on global
improvement.
Sensitivity analyses of the comparisons to active manual
controls revealed robust CST effects on pain intensity and
functional disability post intervention against the risk of se-
lection, detection, attrition, and reporting bias.
However, most of the sensitivity analyses included only one
remaining RCT that had a low risk of the respective bias, with
the exception of the analyses of pain intensity and functional
disability in comparison to sham post intervention. These
meta-analyses included always 2 to 3 of the 4 initially analyzed
RCTs. Detailed analyses can be found in the Additional file 1.
Fig. 6 Forest plot of physical quality of life
Fig. 7 Forest plot of mental quality of life
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Safety
Five RCTs [35–37, 42, 44] provided no information
about AEs. Two RCTs stated no withdrawal due to AEs
[38, 39], while another reported no AEs at all [43]. The
two remaining RCTs found 5 and 7 minor AEs in the
CST group in comparison to 6 and 9 minor AEs in the
groups receiving treatment as usual [40] and manual
sham [41]. Minor AEs during or subsequent to the CST
treatment included increased intensity of pain, headache,
shivering, drowsiness, tiredness, and strong emotional
reactions such as weeping. No serious adverse events
were reported [40, 41].
Discussion
Summary of evidence
The systematic search revealed 10 RCTs investigating
the efficacy and effectiveness of CST in pain patients
with different chronic diagnoses. In comparison to treat-
ment as usual, this meta-analysis found significant small
to medium size pooled effects of CST directly after the
end of the intervention for: pain intensity, functional dis-
ability, and physical quality of life, which was however
based mainly on one RCT in patients with pelvic girdle
pain. The effects on pain intensity were not robust
against all, but one risk of bias domain; those on func-
tional disability and physical quality were not robust
against the risk of performance, detection and other bias.
In comparison to manual and non-manual sham con-
trols, CST resulted in significantly greater pooled effects
of a medium to large size directly after the end of the
intervention as well as six months after randomization
for pain intensity, functional disability, physical quality
of life, and global improvement. Effects tended to be
higher in comparisons of studies with blinded patients
as well as patients with neck pain or lateral epicondylitis
compared to those with fibromyalgia or migraine. Six
months after randomization, mental quality of life was
no longer found to be significantly different to sham. All
analyses towards sham were robust against all risk of
bias domains, except for the effects of CST on physical
and mental quality of life post intervention that were
found to be robust only against the risk of attrition and
reporting bias. In comparison to another active manual
control, post-intervention data were available for meta-
analysis of the effects on pain intensity and functional
disability in patients suffering from low back pain. Both
comparisons revealed significantly greater medium effect
sizes in favor of CST and were robust against the risk of
selection, detection, attrition, and reporting bias. No ser-
ious AEs were reported. Minor AEs were equally distrib-
uted between the groups, while patients receiving CST
tended to report less AEs than those randomized to the
treatment as usual or manual sham group. In general,
however, the included RCTs did not sufficiently report
adverse events.
Advances on prior systematic reviews
In comparison to prior systematic reviews that included
observational studies and RCTs [20], mixed cranial
osteopathic and CST techniques [22], and healthy and
clinical participants [24], this analysis focused on RCTs
investigating CST in patients with chronic pain diagno-
ses. By searching published as well as unpublished stud-
ies, we were able to include one additional RCT that
showed less positive results and was missed by the previ-
ous reviews [35]. Thus, we performed the first meta-
Fig. 8 Forest plot of global improvement
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analysis of CST trials that revealed no statistical hetero-
geneity except for one follow-up analysis; although it
contained some clinical heterogeneity regarding the
length of the CST interventions and the pain diagnoses
of the patients. A further important issue for research
and clinical practice are safety analyses that are not part
of many previous reviews of CST [22, 24, 46].
Limitations of the review
The first limitation is the small number of studies in-
cluded in the meta-analysis. Conclusions drawn, espe-
cially those from analyses that included only 2 RCTs,
remain preliminary [26]. We used Hedges’ correction for
small samples and found no statistical heterogeneity in
almost all meta-analyses, but adding a few more studies
may change the significance of the results. Additionally,
the large effect on global improvement may be overesti-
mated, as retrospective data tend to be more vulnerable
to recall biases [47]. A second limitation is the often un-
clear risk of bias profile of the included RCTs. Many
RCTs did not report allocation concealment, blinding of
outcome assessment, and alternative methods of de-
creasing the risk of performance bias. Risk of bias assess-
ment may be influenced by the fact that four of the
review authors (HH, RL, GD, and HC) conducted one of
the included RCTs. However, a fifth review author (TS)
independently assessed the risk of bias of the RCTs. As a
result, we do not substantially deviate from the risk of
bias assessment performed by previous reviews [20, 22].
The third limitation is a lack of subgroup analyses. We
were neither able to derive conclusions about CST effi-
cacy or effectiveness for special pain diagnoses, nor for
the requisite number of treatment sessions. The fourth
limitation is the focus on patient-reported outcomes,
which are more vulnerable to the risk of detection bias.
A fact that reduces the reliability of specific CST effects
[22]. However, two of the included RCTs [41, 44]
blinded patients to group allocation effectively; and three
[39, 41, 44] used additional objective measures of pain
and function, which in part led to short-term effects
comparable to those assessed with self-reported mea-
sures. Another point that argues against specific CST ef-
fects is the mostly unclear or high risk of performance
bias due to the lack of blinding therapists to group allo-
cation. This issue was only controlled within one sham-
controlled RCT [41] that showed that the quality of
therapeutic alliance, rated by the blinded patients, did
not significantly influence patient-reported outcomes
[45]. Additionally, the light-touch sham control group
used was credible to patients. Analyses confirmed that
both expectation and credibility ratings were no signifi-
cant predictors of group allocation [45]. In contrast,
other control groups used in the analyzed RCTs did not
achieve comparable levels of expectation or credibility
compared to CST [48]. Besides, results gained from
waiting list and comparative effectiveness trials should
be interpreted with restraint as none of the RCTs con-
trolled for patient expectations. Thus, placebo effects on
pain cannot be excluded, although they were calculated
as ranging just between a SMD of − 0.35 and − 0.16 [49].
Implications for further research
Further clinical trials on CST are required. Authors
should ensure rigorous methodology and reporting [50]
as well as adequate controls for nonspecific therapy and
therapist effects in order to reduce the risk of perform-
ance and detection bias. Even though therapists could
not be blinded, controlling for attention effects by e.g.
asking the patients about their perception of the thera-
peutic alliance [51] would be feasible. In waiting list or
comparative effectiveness trials, where patients could
not be blinded, patients’ expectations should be opera-
tionalized as a covariate and included in statistical ana-
lyses. In general, more adequate statistics (including
intention-to-treat analyses as well as alpha-level adjust-
ment for multiple testing) would ensure a low risk of
attrition bias and other sources of bias. Increased atten-
tion should also be drawn to the adequate assessment
and reporting of AEs and reasons for drop-out.
Implications for clinical practice
The summarized evidence suggests robust short-term
efficacy and comparative effectiveness of CST on pain
intensity and functional disability. Longer-term effects
seem plausible as well. According to this meta-
analysis, CST was not associated with serious adverse
events. However, clinicians should be aware of the
potential risks of forcibly applied spinal CST tech-
niques, which ca be associated with serious AEs, par-
ticularly in patients with preexisting pathologies of
the spine [52]. Nonetheless, CST seem to be as safe
as other conventional or commentary manual treat-
ments [52] and might provide a novel treatment op-
tion in cases where standard treatments have failed to
cause symptom alleviation. Recommendations for spe-
cific pain conditions cannot be given.
Conclusions
This meta-analysis suggests significant and robust effects
of CST on pain and function, which are not exclusively
explainable by placebo responses or effects due to non-
specific treatment mechanisms. More RCTs strictly fol-
lowing CONSORT are needed to further corroborate the
efficacy, comparative effectiveness, and safety of CST in
patients with chronic pain conditions.
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